drugset / Trial / NCT00003058

Troglitazone in Treating Patients With Liposarcoma

NCT00003058 ↗

NaSingle-groupOpen-labelTreatment

Summary

Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype.

Timeline

Start
1997-06
Primary completion
2000-01
Completion
2000-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject troglitazone Small molecule 800 mg Oral

Indications